Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Fall Home Improvement
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Argenx Se ADR
(NQ:
ARGX
)
367.15
-1.45 (-0.39%)
Streaming Delayed Price
Updated: 9:31 AM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Argenx Se ADR
< Previous
1
2
3
4
5
6
7
Next >
The Analyst Verdict: argenx In The Eyes Of 12 Experts
April 18, 2024
Via
Benzinga
Cartesian Therapeutics' Rare Disease Candidate Shows Long Lasting Benefit Over Argenx's Vyvgart, Analyst Initiates With Buy
April 10, 2024
Cartesian Therapeutics' autoimmune disease treatment with re-dosable mRNA CAR-Ts. Learn about Descartes-08, a promising anti-BCMA CAR-T therapy offering deeper, longer-lasting efficacy than current...
Via
Benzinga
Key Takeaways From argenx Analyst Ratings
March 26, 2024
Via
Benzinga
Tesla To $120? Here Are 10 Top Analyst Forecasts For Tuesday
March 26, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Guess? Posts Upbeat Earnings, Joins Lufax, Nortech Systems And Other Big Stocks Moving Higher On Thursday
March 21, 2024
U.S. stocks were higher, with the Dow Jones index gaining around 250 points on Thursday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Earnings Scheduled For February 29, 2024
February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.
Via
Benzinga
Why Is Argenx (ARGX) Stock Down 25% Today?
December 20, 2023
Following a late-stage clinical disappointment, Argenx has been forced back to the drawing board, thus cratering ARGX stock.
Via
InvestorPlace
Argenx Dives On Autoimmune Therapy Failure
December 20, 2023
A treatment for a skin-blistering condition failed to beat a placebo.
Via
Investor's Business Daily
Why FactSet Research Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
March 21, 2024
Shares of FactSet Research Systems Inc. (NYSE: FDS) fell sharply during Thursday’s session after the company reported worse-than-expected second-quarter revenue and issued FY24 guidance.
Via
Benzinga
Why Is European Pharma Giant Argenx Valued At Over $20B Trading Higher On Thursday?
March 21, 2024
Argenx shares rise on Chugai's gMG trial disappointment. FDA-approved Vyvgart for anti-acetylcholine receptor antibody-positive adult patients. Enspryng's Phase 3 study results disappoint. Vyvgart...
Via
Benzinga
Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results
March 21, 2024
Investors saw Chugai's experimental drug as a potential rival to Argenx's approved medicine, Vyvgart.
Via
Investor's Business Daily
Stifel Maintains Buy Rating for argenx: Here's What You Need To Know
December 18, 2023
Via
Benzinga
Here's How Much $1000 Invested In argenx 5 Years Ago Would Be Worth Today
December 01, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
March 21, 2024
Via
Benzinga
Why Micron Therapies Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
March 21, 2024
Shares of Micron Technology, Inc. (NASDAQ: MU) rose sharply in today’s pre-market trading as the company reported upbeat results for its second quarter and issued
Via
Benzinga
3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition
February 21, 2024
Now could be the time to start looking into these biotech stocks as there are imminent approvals on their clinical trials.
Via
InvestorPlace
New Hope For Patients With Chronic Autoimmune Conditions: Johnson & Johnson's Investigational Drug Meets Primary Goal In Two Studies
February 05, 2024
Johnson & Johnson's nipocalimab shows promise in Phase 3 VIVACITY for gMG & Phase 2 DAHLIAS for SjD. FDA-approved Vyvgart Hytrulo for gMG.
Via
Benzinga
Halozyme's Ambitious Five-Year Plan: Analysts Optimistic On Growth, Eyeing Market Expansion
January 18, 2024
Explore Halozyme Therapeutics' promising financial outlook up to 2028. Discover revenue forecasts, earnings projections, and market insights.
Via
Benzinga
5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond
January 15, 2024
These five biotech companies could have a lot of room to run.
Via
The Motley Fool
Stock Market Rally Is In Merry Mood Heading Into Christmas Weekend: Weekly Review
December 22, 2023
Despite a Wednesday tumble, the major indexes are right at 2023 highs.
Via
Investor's Business Daily
Argenx's Autoimmune Trial Stumble: Analysts Cut Price Targets, Warn of Risky Outcomes
December 21, 2023
Wednesday, Argenx SE (NASDAQ: ARGX) released topline results from the ADDRESS Phase 3 study evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with pemphigus...
Via
Benzinga
Immunovant Scores Much-Needed Win Following Argenx-Led Sell-off
December 21, 2023
Immunovant reversed its fortunes Thursday following an Argenx-tied selloff Wednesday.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Thursday's Pre-Market Session
December 21, 2023
Via
Benzinga
Amazon.com To Rally Over 38%? Here Are 10 Top Analyst Forecasts For Thursday
December 21, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Why Steelcase Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
December 20, 2023
Steelcase Inc. (NYSE: SCS) shares moved higher during Wednesday's session following quarterly results.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
December 20, 2023
Via
Benzinga
Why Is European Drugmaker Argenx Stock Sinking Today?
December 20, 2023
Argenx SE (NASDAQ: ARGX) shares plunged after the company released topline results from the ADDRESS Phase 3 study evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in...
Via
Benzinga
Why Aclarion Shares Are Trading Higher By Around 53%; Here Are 20 Stocks Moving Premarket
December 20, 2023
Shares of Aclarion, Inc. (NASDAQ: ACON) shares rose sharply in pre-market trading after the company was granted U.S. patent #11844601 for "MR SPECTROSCOPY SYSTEM FOR DIAGNOSING PAINFUL AND NON-PAINFUL...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
December 20, 2023
Via
Benzinga
FedEx Posts Downbeat Earnings, Joins Steelcase, argenx And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
December 20, 2023
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 30 points on Wednesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.